View Post

Chemotherapy-Free Drug Combination Shows PFS Benefit for Women With HER2-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Hopkins From: Results from the Phase II monarcHER study published last week in Lancet Oncology demonstrated that women with advanced HER2-positive breast cancer may benefit from a combination of three non-chemotherapy agents: the CDK4/CDK6 inhibitor abemaciclib (Lilly’s Verzenio), the HER2-targeted therapy trastuzumab (Genentech’s Herceptin), and the anti-estrogen therapy fulvestrant (AstraZeneca’s Faslodex). The study showed a significant improvement …